European Regulatory Requirements for the Development, Evaluation, and Approval of Oncology Products

balance before marketing authorization and throughout their life cycle. The European Union has established a harmonized regulatory framework involving the European Medicines Agency, the European Commission, and national competent authorities. This research provides a regulatory framework and marketing authorization process applicable to oncology medicinal products in the European Commission. The pharmaceutical quality, non-clinical evaluation, clinical development, benefit–risk assessment, pharmacovigilance, risk management, and post-marketing obligations are discussed. The challenges associated with limited patient populations, rapidly evolving therapeutic strategies, complex clinical endpoints, and the need for expedited access to innovative cancer therapies. The importance of regulatory planning throughout the product life cycle to address evolving scientific, clinical, and safety requirements. This is intended to provide researchers, pharmaceutical professionals, and regulatory-affairs personnel with a clear understanding of European regulatory requirements for oncology products and to emphasize the role of effective regulatory strategies in facilitating timely access to safe, effective, and highquality cancer therapies.